We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Innovative Von Willebrand Factor Test Launched in US

By LabMedica International staff writers
Posted on 18 Apr 2017
A center for blood diseases has launched a new test in the United States to more accurately measure activity of von Willebrand Factor (VWF), one of the blood-clotting proteins, for people with the inherited bleeding disorder von Willebrand disease (VWD).

The new assay – “VWF GPIbM Activity” – was launched by BloodCenter of Wisconsin (Milwaukee, WI, USA), part of Versiti. More...
The test employs patented technology previously not used in the USA that provides more precise measurement of VWF platelet-binding activity – critical for making an accurate diagnosis of VWD. BloodCenter of Wisconsin is the first organization to make this test available in the US in a clinical laboratory setting.

Though there is no cure for VWD, treatment can help prevent or stop bleeding episodes. Making the most accurate diagnosis is critical to identifying the most appropriate treatment to manage the disease.

VWF GPIbM Activity detects qualitative VWF defects, reducing variability and providing more precise, reliable, and sensitive test results. Clinical hematologists can thus be more confident that the results reflect their patient’s clinical scenario.

“As a physician caring for individuals with inherited bleeding disorders, this development is an exciting advancement in von Willebrand disease diagnostics,” said Johnathan Roberts, MD, of the Bleeding & Clotting Disorders Institute (Peoria, IL, USA), “This assay will reduce some of the diagnostic challenges in caring for individuals with VWD.”


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.